UK Markets open in 6 hrs 40 mins

CureVac N.V. (CVAC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
41.08+2.29 (+5.90%)
At close: 04:00PM EST
Full screen
Loading interactive chart…
  • Motley Fool

    CureVac (CVAC) Q3 2021 Earnings Call Transcript

    On the call with me from CureVac are Franz-Werner Haas, the chief executive officer of CureVac; Klaus Edvardsen, our chief development officer; and Pierre Kemula, chief financial officer of CureVac. Mariola Fotin-Mleczek, our chief technology officer, will be available for the Q&A session.

  • EQS Group

    CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update

    DGAP-News: CureVac / Key word(s): Quarter Results18.11.2021 / 22:10 The issuer is solely responsible for the content of this announcement.CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update - Strategic focusing on second-generation mRNA program jointly developed with GSK after withdrawal of first-generation COVID-19 vaccine candidate, CVnCoV, from regulatory review- Nature publication of promising pre-clinical results for second-ge

  • EQS Group

    CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine

    DGAP-News: CureVac / Key word(s): Scientific publication18.11.2021 / 11:42 The issuer is solely responsible for the content of this announcement.CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA VaccineTÜBINGEN, Germany/ BOSTON, USA - November 18, 2021 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucle